中国现代医生杂志欢迎您.   今天是:          
黄 钦 殷颖杰 方晶晶 史超路 颜碧清▲.低分子肝素在脓毒症致急性肺损伤中的治疗效果及其对VAS的影响[J].中国现代医生,2021,59(3):81-84
低分子肝素在脓毒症致急性肺损伤中的治疗效果及其对VAS的影响
Effect of low molecular weight heparin in the treatment of acute lung injury caused by sepsis and its effect on VAS
  
DOI:
中文关键词:  低分子肝素  脓毒症  急性肺损伤  治疗效果  VAS 评分
英文关键词:Low molecular weight heparin  Sepsis  Acute lung injury  Therapeutic effect  VAS score
基金项目:浙江省宁波市医学科技计划项目(2018A10)
作者单位
黄 钦 殷颖杰 方晶晶 史超路 颜碧清▲ 宁波大学医学院附属医院ICU浙江宁波 315020 
摘要点击次数: 477
全文下载次数: 1326
中文摘要:
      目的 探讨低分子肝素在脓毒症致急性肺损伤中的治疗效果及其对VAS 的影响。方法 选取2017 年1 月至2019 年1 月在我院接收治疗的脓毒症致急性肺损伤患者84 例,根据随机数字法分为研究组和对照组,每组各42 例。对照组采用常规方法治疗,研究组采用低分子肝素治疗。观察两组患者的治疗有效率、Murray 肺损伤和VAS 评分、CRP 和PCT 水平以及PLT。结果 研究组的总有效率为97.62%,明显高于对照组的80.95%,差异有统计学意义(P<0.05)。治疗后,研究组Murray 肺损伤评分为(1.10±0.30)分、VAS 评分为(2.50±0.50)分,明显低于对照组的(2.30±0.60)分、(4.70±0.60)分,差异有统计学意义(P<0.05)。治疗后,研究组CRP 为(55.70±17.30)mg/L、PCT 水平为(2.70±1.20)ng/mL,明显低于对照组的(83.10±18.10)mg/L、(3.60±1.10)ng/mL,差异有统计学意义(P<0.05),研究组PLT 为(217.30±18.70)×109/L,明显高于对照组的(199.10±16.30)×109/L,差异有统计学意义(P<0.05)。结论 对脓毒症致急性肺损伤患者的治疗过程中使用低分子肝素治疗效果显著,不仅能降低患者肺部功能的损伤和疼痛,还能有效抑制机体凝血功能的异常,减少血小板不正常的消耗,降低炎症反应对机体造成的伤害,值得在临床上大力推广应用。
英文摘要:
      Objective To explore the therapeutic effect of low molecular weight heparin in acute lung injury caused by sepsis and its effect on VAS.Methods A total of 84 patients with acute lung injury caused by sepsis who were treated in our hospital from January 2017 to January 2019 were selected.They were divided into the study group and the control group according to the random number method,with 42 cases in each group.The control group was treated with conventional methods,and the study group was treated with low molecular weight heparin.The treatment efficiency,Murray lung injury and VAS scores,CRP protein,PCT levels,and platelet counts were observed in the both groups of patients.Results The total rate of treatment effect(97.62%) in the study group was higher than that of(80.95%) in the control group,with significant difference(P<0.05);the Murray lung injury score was(1.10±0.30) point,the VAS score was(2.50±0.50) point in the study group,which were lower than those of(2.30±0.60) point,(4.70±0.60) point in the control group,with significant differences(P<0.05);the CRP (55.70±17.30) mg/L and PCT level(2.70±1.20) ng/mL in the study group,which were lower than those of (83.10±18.10) mg/L and(3.60±1.10) ng/mL in the control group,with significant differences(P<0.05).The number of platelets(217.30±18.70) ×109/L in the study group,which was higher than that of(199.10±16.30)×109/L in the control group,with significant difference(P<0.05).Conclusion The use of low molecular weight heparin in the treatment of patients with acute lung injury caused by sepsis has a significant therapeutic effect,which can not only reduce the lung function injury of patients and alleviate the pain,but also effectively inhibit the abnormal progress of the patient's coagulation function,reduce the abnormal consumption of platelets,and reduce the damage caused by the inflammatory reaction to the body,which is worthy of vigorous clinical promotion and application.
查看全文  查看/发表评论  下载PDF阅读器
关闭
    • 关键词 :
    • 中国医生
    • 中国现代医生
    • 中国临床医生
    • 中国医师
    • 主任医师
    • 中国医学
    • 中华医学
    • 中国医院
    • 中国医药
    • 中国医疗
    • 现代医生
    • 现代医学
    • 现代医药
    • 现代医院
    • 现代药物
    • 现代护理
    • 现代临床
    • 医学杂志
    • 药学杂志
    • 医药杂志
    • 医生杂志
    • 医师杂志
    • 医疗杂志
    • 医药期刊
    • 医学期刊
    • 医药卫生期刊
    • 医药论文
    • 医学论文
    • 科研论文
    • 职称论文
    function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=FF4EC6B96077DFE79657AA8ABE2F4E115108AD2D347C18F336D0306830E3D1EBC521AC53D9B0D7560045F7DC919614EEE4C6B927E40E168ADAA6D26415933E3A2298977BF9B2320540CDBEE96D067991D4C18FA4B46D83457D0D998D742FD3D941834AE6F762E43DBE071E27B3578795F8B38A949169C943&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=8EDAEC11C165015425CEEA15366CB0A7&yid=9475FABC7A03F4AB&aid=&vid=&iid=38B194292C032A66&sid=35FC3610259C2B32&eid=656F8C8401D91023&fileno=2021902&flag=1&is_more=0">